



Fitch Affirms Ache's IDR at 'BB'; Outlook Stable

Fitch Ratings-Rio de Janeiro-11 February 2019: Fitch Ratings has affirmed Ache Laboratorios Farmaceuticos S.A.'s (Ache) Long-Term, Foreign-Currency Issuer Default Rating (FC IDR) at 'BB', Long-Term, Local-Currency IDR (LC IDR) at 'BBB' and its National Scale Rating at 'AAA(bra)'. The Rating Outlook is Stable for the FC IDR, the LC IDR and the National Scale Rating. A full list of ratings follows at the end of this release.

Ache's investment-grade LC IDR reflects the defensive nature of the pharmaceutical industry, which translates into a low level of cash flow volatility during a five year rating period, and its strong business position in the Brazilian pharmaceutical market with a leadership position in the prescription drug segment. Ache has higher margins than its Brazilian peers due to its mix portfolio, focused on the prescription segment, strong brands that get pricing premiums and its market-leading size, which helps fixed-cost dilution. The company's position is viewed to be sustainable due to its large sales team that gives it a key competitive advantage in terms of outreach to the medical community and brand awareness.

Ache's financial profile resembles that of global peers rated in the 'A' category because of its low debt levels relative to cash flow, high cash balance and strong FCF generation before dividends. The ratings incorporate Fitch's expectation that Ache will remain committed to an unleveraged capital structure, while managing its growth with cash flow supporting organic growth and small acquisitions. Fitch expects net leverage ratios to remain below 0.5x in the next four years. Ache has had a shareholder-friendly dividends policy, but Fitch considers that the company has flexibility to adjust payouts if necessary to avoid deterioration of its credit metrics due to the fact that ownership of the company is concentrated in three families.

Ache's LC IDR has been constrained at 'BBB' by its lack of geographic diversification, as the company generates essentially all of its cash flow in Brazil, a country with high operating risk. The company also does not have the size or global market positions of peers rated in the 'A' category such as Pfizer, Merck and Bristol-Myers Squibb. Ache's 'BB' FC IDR is capped by Brazil's Country Ceiling (BB), as the company's operations are essentially in Brazil and it does not have substantial assets or cash held abroad to help mitigate transfer and convertibility risk.

KEY RATING DRIVERS

Solid Business Profile: Ache has a solid and recognized brand in the Brazilian pharmaceutical industry. Its diversified product portfolio, leadership in the prescription drugs segment, and presence in the fast-growing over-the-counter (OTC), generics and dermo-cosmetics segments support its sound business profile. Ache is the fourth-largest laboratory in Brazil and has one of the largest sales forces in the domestic market, which provides a key competitive advantage compared with local and international peers. This allows an extensive outreach to the medical community, which is crucial for having its products receive prescriptions.

Low Product-Portfolio Risk: Ache's operating cash flow is not exposed to license renewals or patent expirations. Similar to other emerging-markets pharmaceutical companies, Ache has a narrower research and development (R&D) product pipeline than its multinational competitors and has a weaker portfolio of patented products. Positively, the company's exposure to licensing agreements is low, representing less than 10% of revenues from these products. Ache has consistently been increasing its efforts to innovate and renovate its product portfolio by investing about 2.5% of its revenues in R&D. During 2019, Fitch expects product launches to reach more than 20% of revenues from 16% in 2012.

Increasing Competition: Over the last few years, competition has increased with the local pharmaceutical players consolidating brands and expanding their product reach across segments and therapeutic classes. Also, some competitors started to present their market position under group basis instead of single entities. As a result, Ache lost two market positions in the total Brazilian pharmaceutical market, becoming the fourth-largest player in terms of net revenues. In its key segment, prescription segment, Ache is the second largest with a 6.8% market-share. Fitch expects Ache's margins to be under pressure at the 28%-30% range but it remains adequate in comparison with the average of the industry. Increased competition has led to higher product development and marketing expenses. Fitch believes that Ache's Brazilian operating expertise and strong distribution system are key factors to help to mitigate this increasing competition.

CFFO to Remain Sound: Fitch expects Ache's cash flow from operations (CFFO) to remain robust despite increased competition. Ache's net revenue and EBITDA during the LTM ended Sept. 30, 2018 were BRL3.2 billion and BRL980 million, respectively, with EBITDA margins at 30.3%. These figures compare with net revenues of BRL2.9 billion and EBITDA of BRL871 million in 2017, with an EBITDA margin of 29.4%. Fitch forecasts the company's EBITDA margin will move to around 28%-30%, a decline from the 32%-35% range over the last four years. FFO and CFFO remained strong, at BRL813 million and BRL694 million, respectively, during the same period.

Dividends and Capex to Pressure FCF: Ache has a track record of maintaining an aggressive shareholder-friendly policy, which has led to negative FCF since 2012, with 2017 being the exception with a positive FCF of BRL26 million. Between 2012 and 2016, Ache generated an average negative FCF of BRL55 million. Dividend distributions averaged BRL405 million per year in the period, around 90% dividends payouts. Fitch expects that in a more challenging scenario, the company would pursue a more conservative dividend policy in order to increase its financial flexibility and sustain its strong capital structure. This assumption takes into consideration Ache's plan to expand its capacity by 50% with a new production facility in Permanbuco, with estimated costs of BRL600 million. During the LTM ended September 2018, Ache generated negative FCF of BRL150 million, after BRL185 million capex and BRL533 million of dividend pay-outs (around 85% of net income).

Unleveraged Capital Structure: Ache has historically maintained low leverage ratios, and its credit measures continue to be quite strong. Fitch's projections indicate a net debt/EBITDA ratio remaining below 0.5x in the next four years. Fitch's base case scenario incorporates the new capex for the new facility and around 80% of dividends payout. In the past five years, the company's average leverage, as measured by the FFO-adjusted leverage ratio, was 0.4x, while its net debt/EBITDA ratio was negative at 0.2x.

DERIVATION SUMMARY

Ache's LC IDR and National Scale 'BBB'/AAA(bra) ratings reflect the defensive nature of the pharmaceutical industry, its leading position in the prescription drug segment and low product portfolio risk with no exposure to patents or licenses. Ache's lack of geographic diversification, lower business scale, relatively narrower research portfolio and credit access/financial flexibility compared with top pharmaceutical companies currently constrains its 'BBB' local-currency ratings. Ache is well positioned in terms of profitability and leverage compared with most of the top global pharmaceutical issuers that are rated 'A'/AA' by Fitch, with average EBITDA margin of 31% and average net leverage of 1.5x.

In comparison with others Brazilian issuers in Fitch's rated universe, Ache's business resilience to economic cycles, strong CFFO generation, financial flexibility as well as its unleveraged capital structure stands out amongst its peers. Fitch's 'BBB' portfolio average net leverage, measured by net debt/EBITDA, is 2.2x. Ache's capital structure has consistently been stronger. During the next four years, Fitch projects the company's net leverage will remain below 0.5x. Ache's operations being concentrated in Brazil and lack of operating/financial assets abroad cap its ratings at the Brazilian Country Ceiling of 'BB'.

KEY ASSUMPTIONS

- Revenue growth close to 10% from 2019 to 2021;
- Innovation to continue to represent around 20% of revenues (R&D expenses of around 2% of revenue);

- EBITDA margin in the range of 28%-30% due to increasing SG&A related to diversification of the portfolio;
- Capex of BRL785 million from 2019-2021, which includes the construction of the new plant in Pernambuco;
- Maintenance of the high dividend pay-outs at around 80% of net income.

RATING SENSITIVITIES

Developments That May, Individually or Collectively, Lead to Positive Rating Action

For the Foreign-Currency IDR, positive rating actions are limited by Brazil's country ceiling of 'BB', while for the Local Currency IDR of 'BBB', an upgrade is unlikely in the medium term.

Developments That May, Individually or Collectively, Lead to Negative Rating Action

Ache's credit ratios are very strong at the current rating level, but unexpected events that move the company's net bet/EBITDA beyond 2.0x or FFO-adjusted leverage beyond 3.0x could result in negative rating action for the Local Currency IDR or National Scale Rating. Significant market-share or brand deterioration could also trigger a downgrade. A further negative rating action on Brazil's sovereign ratings and country ceiling could also result in negative rating action for the company's foreign-currency IDR.

LIQUIDITY

Robust Liquidity: Ache has historically held a robust liquidity position. As of Sept. 30, 2018, Ache's cash balances covered its short-term debt by 3.3x. As of the same date, the company reported BRL154 million of cash and marketable securities and total adjusted debt of BRL243 million, of which BRL46 million was short-term. About 85% of Ache's debt is with the Brazilian Development Bank (BNDES).

FULL LIST OF RATING ACTIONS

Fitch has affirmed the following ratings:

Ache Laboratorios Farmaceuticos S.A. (Ache):

- Foreign Currency Issuer Default Rating (IDR) at 'BB'; Outlook Stable;
- Local currency IDR at 'BBB'; Outlook Stable;
- National Scale rating at 'AAA(bra)'; Outlook Stable.

Contact:

Primary Analyst

Renato Mota, CFA, CAIA

Associate Director

+55 21 4503-2629

Fitch Ratings Brasil Ltda.

Av. Barao de Tefe, 27 - Sala 601 - Saude

Rio de Janeiro - RJ - CEP: 20220-460

Secondary Analyst

Debora Jalles

Director

+1-312-606-2338

Committee Chairperson

Ricardo Carvalho

Managing Director

+55 21 4503-2627

Media Relations: Alyssa Castelli, New York, Tel: +1 212 908 0540, Email: alyssa.castelli@thefitchgroup.com

Additional information is available on www.fitchratings.com

Applicable Criteria

Corporate Rating Criteria (pub. 23 Mar 2018)

National Scale Ratings Criteria (pub. 18 Jul 2018)

Additional Disclosures

Dodd-Frank Rating Information Disclosure Form

Solicitation Status

Endorsement Policy

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:

[HTTPS://WWW.FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS](https://www.fitchratings.com/understandingcreditratings). IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEB SITE AT WWW.FITCHRATINGS.COM. PUBLISHED RATINGS, CRITERIA, AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE, AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE CODE OF CONDUCT SECTION OF THIS SITE. DIRECTORS AND SHAREHOLDERS RELEVANT INTERESTS ARE AVAILABLE AT [HTTPS://WWW.FITCHRATINGS.COM/SITE/REGULATORY](https://www.fitchratings.com/site/regulatory). FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.

Copyright © 2019 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Fax: (212) 480-4435. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved. In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification it obtains will vary depending on the nature of the rated security and its issuer, the requirements and practices in the jurisdiction in which the rated security is offered and sold and/or the issuer is located, the availability and nature of relevant public information, access to the management of the issuer and its advisers, the availability of pre-existing third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third-party verification sources with respect to the particular security or in the particular jurisdiction of the issuer, and a variety of other factors. Users of Fitch's ratings and reports should understand that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to financial statements and attorneys with respect to legal and tax matters. Further, ratings and forecasts of financial and other information are inherently forward-looking and embody assumptions and predictions about future events that by their nature cannot be verified as facts. As a result, despite any verification of current facts, ratings and forecasts can be affected by future events or conditions that were not anticipated at the time a rating or forecast was issued or affirmed.

The information in this report is provided "as is" without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch are based on established criteria and methodologies that Fitch is continuously evaluating and updating. Therefore, ratings and reports are the collective work product of Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is

specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectus nor a substitute for the information assembled, verified and presented to investors by the issuer and its agents in connection with the sale of the securities. Ratings may be changed or withdrawn at any time for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any sort. Ratings are not a recommendation to buy, sell, or hold any security. Ratings do not comment on the adequacy of market price, the suitability of any security for a particular investor, or the tax-exempt nature or taxability of payments made in respect to any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US\$1,000 to US\$750,000 (or the applicable currency equivalent) per issue. In certain cases, Fitch will rate all or a number of issues issued by a particular issuer, or insured or guaranteed by a particular insurer or guarantor, for a single annual fee. Such fees are expected to vary from US\$10,000 to US\$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with any registration statement filed under the United States securities laws, the Financial Services and Markets Act of 2000 of the United Kingdom, or the securities laws of any particular jurisdiction. Due to the relative efficiency of electronic publishing and distribution, Fitch research may be available to electronic subscribers up to three days earlier than to print subscribers.

For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001

Fitch Ratings, Inc. is registered with the U.S. Securities and Exchange Commission as a Nationally Recognized Statistical Rating Organization (the "NRSRO"). While certain of the NRSRO's credit rating subsidiaries are listed on Item 3 of Form NRSRO and as such are authorized to issue credit ratings on behalf of the NRSRO (see <https://www.fitchratings.com/site/regulatory>), other credit rating subsidiaries are not listed on Form NRSRO (the "non-NRSROs") and therefore credit ratings issued by those subsidiaries are not issued on behalf of the NRSRO. However, non-NRSRO personnel may participate in determining credit ratings issued by or on behalf of the NRSRO.

SOLICITATION STATUS

The ratings above were solicited and assigned or maintained at the request of the rated entity/issuer or a related third party. Any exceptions follow below.

Endorsement Policy

Fitch's approach to ratings endorsement so that ratings produced outside the EU may be used by regulated entities within the EU for regulatory purposes, pursuant to the terms of the EU Regulation with respect to credit rating agencies, can be found on the EU Regulatory Disclosures page. The endorsement status of all International ratings is provided within the entity summary page for each rated entity and in the transaction detail pages for all structured finance transactions on the Fitch website. These disclosures are updated on a daily basis.

Fitch Updates Terms of Use & Privacy Policy

We have updated our Terms of Use and Privacy Policies which cover all of Fitch Group's websites. [Learn more.](#)